Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California. more
Time Frame | BNTC | Sector | S&P500 |
---|---|---|---|
1-Week Return | -9.09% | 0.49% | -1.93% |
1-Month Return | -6.3% | -3.1% | -3.69% |
3-Month Return | 12.13% | -8.59% | 0.82% |
6-Month Return | 15.18% | -4.57% | 3.51% |
1-Year Return | 266.67% | -0.94% | 21.91% |
3-Year Return | -74.22% | 2.88% | 24.73% |
5-Year Return | -91.3% | 35.84% | 78.4% |
10-Year Return | -99.7% | 98.8% | 187.28% |
Jun '20 | Jun '21 | Jun '22 | Jun '23 | Jun '24 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 97.00K | 59.00K | 73.00K | 75.00K | 216.00K | [{"date":"2020-06-30","value":44.91,"profit":true},{"date":"2021-06-30","value":27.31,"profit":true},{"date":"2022-06-30","value":33.8,"profit":true},{"date":"2023-06-30","value":34.72,"profit":true},{"date":"2024-06-30","value":100,"profit":true}] |
Cost of Revenue | 268.06K | 123.00K | 9.00K | 381.00K | 108.00K | [{"date":"2020-06-30","value":70.36,"profit":true},{"date":"2021-06-30","value":32.28,"profit":true},{"date":"2022-06-30","value":2.36,"profit":true},{"date":"2023-06-30","value":100,"profit":true},{"date":"2024-06-30","value":28.35,"profit":true}] |
Gross Profit | (171.06K) | (64.00K) | 64.00K | (306.00K) | 108.00K | [{"date":"2020-06-30","value":-158.39,"profit":false},{"date":"2021-06-30","value":-59.26,"profit":false},{"date":"2022-06-30","value":59.26,"profit":true},{"date":"2023-06-30","value":-283.33,"profit":false},{"date":"2024-06-30","value":100,"profit":true}] |
Gross Margin | (176.36%) | (108.47%) | 87.67% | (408.00%) | 50.00% | [{"date":"2020-06-30","value":-201.16,"profit":false},{"date":"2021-06-30","value":-123.73,"profit":false},{"date":"2022-06-30","value":100,"profit":true},{"date":"2023-06-30","value":-465.38,"profit":false},{"date":"2024-06-30","value":57.03,"profit":true}] |
Operating Expenses | 8.56M | 13.53M | 17.92M | 19.16M | 22.38M | [{"date":"2020-06-30","value":38.26,"profit":true},{"date":"2021-06-30","value":60.46,"profit":true},{"date":"2022-06-30","value":80.06,"profit":true},{"date":"2023-06-30","value":85.59,"profit":true},{"date":"2024-06-30","value":100,"profit":true}] |
Operating Income | (8.28M) | (13.60M) | (17.85M) | (19.08M) | (22.49M) | [{"date":"2020-06-30","value":-828100000,"profit":false},{"date":"2021-06-30","value":-1359600000,"profit":false},{"date":"2022-06-30","value":-1785400000,"profit":false},{"date":"2023-06-30","value":-1908100000,"profit":false},{"date":"2024-06-30","value":-2249000000,"profit":false}] |
Total Non-Operating Income/Expense | 69.00K | (292.00K) | (386.00K) | (514.00K) | 1.02M | [{"date":"2020-06-30","value":6.74,"profit":true},{"date":"2021-06-30","value":-28.52,"profit":false},{"date":"2022-06-30","value":-37.7,"profit":false},{"date":"2023-06-30","value":-50.2,"profit":false},{"date":"2024-06-30","value":100,"profit":true}] |
Pre-Tax Income | (8.27M) | (13.88M) | (18.21M) | (19.56M) | (22.37M) | [{"date":"2020-06-30","value":-827400000,"profit":false},{"date":"2021-06-30","value":-1388200000,"profit":false},{"date":"2022-06-30","value":-1820800000,"profit":false},{"date":"2023-06-30","value":-1956200000,"profit":false},{"date":"2024-06-30","value":-2237000000,"profit":false}] |
Income Taxes | 27.00K | (101.00K) | 354.00K | 3.00K | (619.00K) | [{"date":"2020-06-30","value":7.63,"profit":true},{"date":"2021-06-30","value":-28.53,"profit":false},{"date":"2022-06-30","value":100,"profit":true},{"date":"2023-06-30","value":0.85,"profit":true},{"date":"2024-06-30","value":-174.86,"profit":false}] |
Income After Taxes | (8.30M) | (13.78M) | (18.56M) | (19.57M) | (21.75M) | [{"date":"2020-06-30","value":-830100000,"profit":false},{"date":"2021-06-30","value":-1378100000,"profit":false},{"date":"2022-06-30","value":-1856200000,"profit":false},{"date":"2023-06-30","value":-1956500000,"profit":false},{"date":"2024-06-30","value":-2175100000,"profit":false}] |
Income From Continuous Operations | (8.27M) | (13.88M) | (18.21M) | (19.56M) | (21.75M) | [{"date":"2020-06-30","value":-827400000,"profit":false},{"date":"2021-06-30","value":-1388200000,"profit":false},{"date":"2022-06-30","value":-1820800000,"profit":false},{"date":"2023-06-30","value":-1956200000,"profit":false},{"date":"2024-06-30","value":-2175100000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-06-30","value":"-","profit":true},{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true}] |
Net Income | (8.30M) | (13.78M) | (18.56M) | (19.56M) | (21.75M) | [{"date":"2020-06-30","value":-830100000,"profit":false},{"date":"2021-06-30","value":-1378100000,"profit":false},{"date":"2022-06-30","value":-1856200000,"profit":false},{"date":"2023-06-30","value":-1956200000,"profit":false},{"date":"2024-06-30","value":-2175100000,"profit":false}] |
EPS (Diluted) | (4.31) | (4.60) | (2.23) | (3.66) | (8.36) | [{"date":"2020-06-30","value":-430.56,"profit":false},{"date":"2021-06-30","value":-460,"profit":false},{"date":"2022-06-30","value":-223,"profit":false},{"date":"2023-06-30","value":-366,"profit":false},{"date":"2024-06-30","value":-836,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
BNTC | |
---|---|
Cash Ratio | 14.90 |
Current Ratio | 15.01 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
BNTC | |
---|---|
ROA (LTM) | -49.60% |
ROE (LTM) | -91.68% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
BNTC | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.07 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.93 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
BNTC | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 2770.13 |
P/B | 3.98 |
Price/FCF | NM |
EV/R | 10457.68 |
EV/Ebitda | 0.27 |
PEG | NM |
Benitec Biopharma Ltd ADR (BNTC) share price today is $10.575
Yes, Indians can buy shares of Benitec Biopharma Ltd ADR (BNTC) on Vested. To buy Benitec Biopharma Ltd ADR from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BNTC stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Benitec Biopharma Ltd ADR (BNTC) via the Vested app. You can start investing in Benitec Biopharma Ltd ADR (BNTC) with a minimum investment of $1.
You can invest in shares of Benitec Biopharma Ltd ADR (BNTC) via Vested in three simple steps:
The 52-week high price of Benitec Biopharma Ltd ADR (BNTC) is $13.29. The 52-week low price of Benitec Biopharma Ltd ADR (BNTC) is $2.69.
The price-to-earnings (P/E) ratio of Benitec Biopharma Ltd ADR (BNTC) is
The price-to-book (P/B) ratio of Benitec Biopharma Ltd ADR (BNTC) is 3.98
The dividend yield of Benitec Biopharma Ltd ADR (BNTC) is 0.00%
The market capitalization of Benitec Biopharma Ltd ADR (BNTC) is $246.91M
The stock symbol (or ticker) of Benitec Biopharma Ltd ADR is BNTC